Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-26-016723
Filing Date
2026-04-24
Accepted
2026-04-24 16:25:16
Documents
22
Period of Report
2026-06-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20065754x1_def14a.htm   iXBRL DEF 14A 1446829
5 GRAPHIC logo_bridgebio2.jpg GRAPHIC 36301
6 GRAPHIC ny20065754x1_piechart01.jpg GRAPHIC 144639
7 GRAPHIC ny20065754x1_piechart03.jpg GRAPHIC 127250
8 GRAPHIC ny20065754x1_pvp01.jpg GRAPHIC 226074
9 GRAPHIC ny20065754x1_pvp02.jpg GRAPHIC 189405
10 GRAPHIC ny20065754x1_pvp03.jpg GRAPHIC 173198
11 GRAPHIC ny20065754x1_pc1.jpg GRAPHIC 707378
12 GRAPHIC ny20065754x1_pc2.jpg GRAPHIC 572489
  Complete submission text file 0001140361-26-016723.txt   8301648

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA bbio-20260622.xsd EX-101.SCH 3571
3 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE bbio-20260622_lab.xml EX-101.LAB 5880
4 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE bbio-20260622_pre.xml EX-101.PRE 1828
25 EXTRACTED XBRL INSTANCE DOCUMENT ny20065754x1_def14a_htm.xml XML 374874
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38959 | Film No.: 26894519
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)